Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Pathogenic gut bacteria" is not a specific molecule or receptor but rather a broad term referring to various bacterial species in the gastrointestinal tract that can cause disease. These include well-known genera and species such as *Klebsiella pneumoniae*, *Bacteroides fragilis*, *Shigella* spp., *Salmonella* spp., and others[1][3]. Pathogenicity arises from their ability to invade host tissues, evade immune responses, and produce toxins that damage host cells or disrupt normal physiological processes[5]. While some are always pathogenic when present in the gut (*Shigella*, *Salmonella*), others may be part of the normal flora but become harmful under certain conditions (*Bacteroides fragilis*)[1][2]. Because "pathogenic gut bacteria" refers to a diverse group rather than a single entity or molecular target, it does not fit standard definitions for therapeutic targets like receptors or enzymes. Instead, it encompasses multiple organisms with varied mechanisms of pathogenesis and drug susceptibility profiles. Treatment typically involves antibiotics tailored to the specific pathogen involved; however, increasing antibiotic resistance among these organisms poses significant therapeutic challenges[4]. In summary: "Pathogenic gut bacterium" is an umbrella term for disease-causing bacterial species in the gastrointestinal tract—not a singular molecular target—and should be replaced by more precise nomenclature when possible.
Inhibition of bacterial cell wall synthesis (e.g., beta-lactams) - Inhibition of protein synthesis (e.g., macrolides)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic gut bacterium.